Admescope is attending CPhI Milan 2026 at Booth 12F38 to discuss process chemistry, solid-state science, formulation, analytical development, and GMP manufacturing.

Admescope, part of the Symeres organization, is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with premium quality tailor-made services to drug discovery in the area of ADME-Tox. Admescope’s unique expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis. The right level of research can always be found for the customer whether in the discovery or lead optimization phase. All of the services include comprehensive study consulting which enables tailoring the study according to customers’ specific needs. The state-of-art quality data is ensured by optimizing the conditions according to the compounds instead of using generic protocols. All of the data can be interpreted for the customer and helped to understand the real meaning of the numerical values and observations. Since 2020, Admescope has been part of Symeres, having capabilities to provide medicinal chemistry and integrated drug discovery and development services via the broader Symeres organization. Service Offering • in vitro Metabolism • in vivo DMPK • Drug Interactions • Quantitative Bioanalysis • Permeability & Transporters • Physicochemistry & Binding • in vitro Toxicology • Biologics • Integrated medicinal chemistry and drug discovery services via Symeres organization

Founded 2011